Tharun is a Chartered Financial Analyst from the CFA Institute, U.S. A graduate from Loyola College, Chennai, he started his career in Goldman Sachs at their Bangalore office. Prior to his current role at Proactive Investors, he worked as an equity analyst at a global research and analytics company in Mumbai, assisting institutional clients across Asia.
CPAT-01 is CP1’s lead pharmaceutical product and is derived from cannabinoids.
The ICCI provides access to a global network of specialist services.
Gold and high-grade copper concentrates will be the primary value drivers at Carlow Castle.
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost price.
Three directors have invested $375,000 to increase their respective shareholdings.
CannaHub is a new addition to the MGC projects currently underway with the Royal Melbourne Institute of Technology, and will be formally launched in Q1 2019.
The company is increasing the capacity of its hemp-derived cannabidiol production facility in the US.